Last reviewed · How we verify
Keloid scar — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Aristospan | TRIAMCINOLONE HEXACETONIDE | Ethypharm | Corticosteroid | Glucocorticoid receptor | 1969-01-01 | |
| Decadron | dexamethasone | Generic (originally Merck) | Corticosteroid [EPC] | Annexin A1, Interleukin-4, Androgen receptor | 1958-10-30 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Keloid scar
- Ethypharm · 1 drug in Keloid scar
- Generic (originally Merck) · 1 drug in Keloid scar
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Keloid scar:
- Keloid scar treatment updates — RSS
- Keloid scar treatment updates — Atom
- Keloid scar treatment updates — JSON
Cite this brief
Drug Landscape (2026). Keloid scar — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/keloid-scar. Accessed 2026-06-10.
Related
- Keloid scar full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing